Michael H. Davidson
Chief Executive Officer at NewAmsterdam Pharma Company N.V.
Sits on 4 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 9 years
- Director since
- 2023
9 years of board service in total across 4 boards, counting each seat separately. Longest: NewAmsterdam Pharma Company N.V., 2 years.
Chief executive roles
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 0
-39.7% a year in revenue
20% of the scoring weight is on file. Figures cover December 2022 – December 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Tenax Therapeutics Inc. June 2, 202689.7%
-
Tenax Therapeutics Inc. June 11, 202580.1%
-
NewAmsterdam Pharma Company N.V. June 4, 202588.4%
-
Tenax Therapeutics Inc. June 7, 202481.5%
-
Tenax Therapeutics Inc. June 9, 202378.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 14, 2026 | NewAmsterdam Pharma Company N.V. | Open-market purchase | +10,000 | $22.65 | $226,500 |
| Mar 2, 2026 | NewAmsterdam Pharma Company N.V. | Option exercise | +443,707 | — | — |
| Mar 2, 2026 | NewAmsterdam Pharma Company N.V. | Open-market sale | −443,707 | $33.25 | $14,753,258 |
| Feb 26, 2026 | NewAmsterdam Pharma Company N.V. | Option exercise | +183,332 | — | — |
| Feb 26, 2026 | NewAmsterdam Pharma Company N.V. | Open-market sale | −165,408 | $33.63 | $5,562,671 |
| Feb 26, 2026 | NewAmsterdam Pharma Company N.V. | Open-market sale | −17,924 | $34.44 | $617,303 |
| Feb 25, 2026 | NewAmsterdam Pharma Company N.V. | Option exercise | +58,253 | — | — |
| Feb 25, 2026 | NewAmsterdam Pharma Company N.V. | Open-market sale | −46,517 | $35.11 | $1,633,212 |
| Feb 25, 2026 | NewAmsterdam Pharma Company N.V. | Open-market sale | −10,436 | $35.96 | $375,279 |
| Feb 25, 2026 | NewAmsterdam Pharma Company N.V. | Open-market sale | −1,300 | $36.68 | $47,684 |
| Feb 24, 2026 | NewAmsterdam Pharma Company N.V. | Option exercise | +64,708 | — | — |
| Feb 24, 2026 | NewAmsterdam Pharma Company N.V. | Open-market sale | −61,547 | $36.13 | $2,223,693 |
| Feb 24, 2026 | NewAmsterdam Pharma Company N.V. | Open-market sale | −3,161 | $36.46 | $115,250 |
| Jan 7, 2026 | NewAmsterdam Pharma Company N.V. | Open-market sale | −11,582 | — | — |
| Jan 7, 2026 | NewAmsterdam Pharma Company N.V. | Grant or award | +81,000 | — | — |
Questions about Michael H. Davidson
What boards is Michael H. Davidson on?
Michael H. Davidson sits on the boards of BioAge Labs Inc., NewAmsterdam Pharma Company N.V., Silence Therapeutics Plc American Depository Share and Tenax Therapeutics Inc.
What company is Michael H. Davidson the CEO of?
Michael H. Davidson has been Chief Executive Officer of NewAmsterdam Pharma Company N.V. since December 2023.
How long has Michael H. Davidson served on boards?
Our records show at least 9 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.